Community Practice

Roche obtains FDA approval for Mircera for dialysis patients, but a patent dispute with Amgen could tie up its marketing in the United States.

New safety information added to rosiglitazone label

NACDS announces Mary Ann Wagner's retirement

A coalition of doctors and scientists has filed a petition with FDA requesting that drugs be tested among humans, rather than animals, where feasible.

CMS has proposed a new rule for the Medicare Part D, which would adopt a new e-prescribing standard.

Rite Aid pharmacies help seniors during Medicare Part D enrollment.

Medco announces its plans to build a 318,000-sq. ft. mail-order pharmacy in Indiana.

Quality of care improving in nation's hospitals.

3M launches new inhaler dose counter.

Miami healthcare company owners in prison for Medicare fraud.

Genzyme has to provide FDA with more data on Synvisc-One before the pain-relieving treatment for osteoarthritis can be approved.

FDA adds new warnings to erythropoiesis-stimulating agents' labels.

New indication for rosuvastatin (Crestor) approved.

U.S. Career Institute announces pharmacy technician course.

Nevada pharmacists demand a vote on Fair Medicaid Drug Payment Act, while House judiciary committee unanimously approves PBM legislation.

A new study finds that Retail clinic's revenues could reach nearly $4.5 billion by 2011.

DEA kicks off exhibit about drug diversion and abuse.

New Web page details POA reporting requirements

Rite Aid responds to union protest

Medicare Part D prescription drug plans owe more than $4 billion to CMS

More than 70,000 medication therapy management services have been offered through the Community Care Rx (CCRx) program, according to an announcement from Mirixa

PDX-NHIN and Health Market Science will jointly market the HMS database with 1.8 million prescriber records including NPI numbers

Michigan Pharmacists Association announces plans for a medication therapy management company to expand MTM opportunities

Giant Eagle expands $4 generic prescription drug program

A new report by the Office of Inspector General found that some generic manufacturers keep raising their drug prices above the inflationary rate, making them deserve to pay more Medicaid rebates